Lead Product(s) : Semaglutide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Accepts Filing for Oral Semaglutide 25 Mg as Potential Obesity Treatment
Details : Wegovy (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist, investigated as oral treatment for chronic weight management in adults living with obesity or overweight.
Product Name : Wegovy
Product Type : Peptide
Upfront Cash : Inapplicable
May 02, 2025
Lead Product(s) : Semaglutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cagrilintide,Semaglutide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CagriSema Shows Superior Weight Loss in REDEFINE 2 Trial for Obesity & Diabetes
Details : CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide and semaglutide. It is being investigated for adults with overweight or obesity.
Product Name : CagriSema
Product Type : Peptide
Upfront Cash : Inapplicable
March 10, 2025
Lead Product(s) : Cagrilintide,Semaglutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Semaglutide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Novo Nordisk: Semaglutide Achieves 20.7% Weight Loss in STEP UP Obesity Trial
Details : Wegovy (semaglutide) is a GLP-1 receptor agonist being investigated in new stregth in adults for chronic weight management & treatment of obesity.
Product Name : Wegovy
Product Type : Peptide
Upfront Cash : Inapplicable
January 17, 2025
Lead Product(s) : Semaglutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cagrilintide,Semaglutide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CagriSema Demonstrates Superior Weight Loss in Adults with Obesity in REDEFINE 1 Trial
Details : CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide and semaglutide. It is being investigated for adults with overweight or obesity.
Product Name : CagriSema
Product Type : Peptide
Upfront Cash : Inapplicable
December 20, 2024
Lead Product(s) : Cagrilintide,Semaglutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Survodutide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase III
Sponsor : Carnegie Investment Bank
Deal Size : $214.0 million
Deal Type : Private Placement
Zealand Pharma Raises DKK 1.45 Billion in Directed Issue and Private Placement
Details : The net proceeds will strengthen Zealand’s investment in assets targeting obesity, including BI 456906 (survodutide), a long-acting glucagon/GLP-1 receptor dual agonist for once-weekly administration.
Product Name : BI 456906
Product Type : Peptide
Upfront Cash : Undisclosed
August 01, 2024
Lead Product(s) : Survodutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase III
Sponsor : Carnegie Investment Bank
Deal Size : $214.0 million
Deal Type : Private Placement
Lead Product(s) : Semaglutide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Wegovy (once-weekly subcutaneous semaglutide 2.4 mg) is a GLP-1 receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults.
Product Name : Wegovy
Product Type : Peptide
Upfront Cash : Inapplicable
August 08, 2023
Lead Product(s) : Semaglutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Semaglutide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Wegovy® (semaglutide) is targeting GLP-1 receptor prescription medicine used along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes.
Product Name : Wegovy
Product Type : Peptide
Upfront Cash : Inapplicable
May 22, 2023
Lead Product(s) : Semaglutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dasiglucagon
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase III
Sponsor : Danske Bank
Deal Size : Undisclosed
Deal Type : Private Placement
Details : The net proceeds will be used for supporting the late stage rare disease assets, including Zegalogue (dasiglucagon), a glucagon analog that acts to increase blood sugar levels, being developed for the treatment of congenital hyperinsulinism.
Product Name : Zegalogue
Product Type : Hormone
Upfront Cash : Undisclosed
March 30, 2023
Lead Product(s) : Dasiglucagon
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase III
Sponsor : Danske Bank
Deal Size : Undisclosed
Deal Type : Private Placement
Lead Product(s) : Semaglutide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Novo Nordisk’s Semaglutide Injection Effective in Weight Loss Trial
Details : Northwestern University Feinberg School of Medicine in the US has reported that results from STEP 1 clinical trial of type-2 diabetes drug semaglutide (Ozempic) once weekly was linked to a sustained, clinically relevant reduction in body weight in obese ...
Product Name : Wegovy
Product Type : Peptide
Upfront Cash : Inapplicable
October 02, 2021
Lead Product(s) : Semaglutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Semaglutide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Novo Nordisk to Initiate Phase 3a Development in Obesity With Oral Semaglutide
Details : The global 68-week trial is planned for initiation in the second half of 2021 and will investigate the efficacy and safety of oral semaglutide compared to placebo.
Product Name : Wegovy
Product Type : Peptide
Upfront Cash : Inapplicable
April 21, 2021
Lead Product(s) : Semaglutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable